INVIVYD, INC. Research and Development Expense
INVIVYD, INC. (IVVD) reported Research and Development Expense of $29.37 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13
- INVIVYD, INC. research and development expense for the quarter ending 2026-06-30 was $29.37M, a 206.77% increase year-over-year.
- INVIVYD, INC. research and development expense for the quarter ending 2026-03-31 was $30.73M, a 188.80% increase year-over-year.
- INVIVYD, INC. research and development expense for the quarter ending 2025-12-31 was $10.05M, a 43.90% decline year-over-year.
- INVIVYD, INC. research and development expense for the quarter ending 2025-09-30 was $8.05M, a 86.09% decline year-over-year.
- INVIVYD, INC. research and development expense for fiscal 2025 was $38.31M, a 72.09% decline from fiscal 2024.
- INVIVYD, INC. research and development expense for fiscal 2024 was $137.25M, a 13.49% decline from fiscal 2023.
- INVIVYD, INC. research and development expense for fiscal 2023 was $158.66M, a 11.47% decline from fiscal 2022.
- INVIVYD, INC. research and development expense for fiscal 2022 was $179.21M.
| Period end | Research and Development Expense 1 month | Research and Development Expense 3 month | Research and Development Expense 4 month | Research and Development Expense 6 month | Research and Development Expense 7 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $29.37M 10-Q · filed 2026-08-13 | $60.10M 10-Q · filed 2026-08-13 | $70.15M derived: sum of 3 quarters · filed 2026-08-13 | $78.19M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2026-03-31 | $30.73M 10-Q · filed 2026-05-14 | $40.78M derived: sum of 2 quarters · filed 2026-05-14 | $48.83M derived: sum of 3 quarters · filed 2026-05-14 | $58.40M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-12-31 | $10.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $18.09M derived: sum of 2 quarters · filed 2026-03-05 | $27.67M derived: sum of 3 quarters · filed 2026-08-13 | $38.31M 10-K · filed 2026-03-05 | |||
| 2025-09-30 | $8.05M 10-Q · filed 2025-11-06 | $17.62M derived: sum of 2 quarters · filed 2026-08-13 | $28.26M 10-Q · filed 2025-11-06 | $46.17M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-06-30 | $9.57M 10-Q · filed 2026-08-13 | $20.21M 10-Q · filed 2026-08-13 | $38.12M derived: sum of 3 quarters · filed 2026-08-13 | $95.97M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-03-31 | $10.64M 10-Q · filed 2026-05-14 | $28.55M derived: sum of 2 quarters · filed 2026-05-14 | $86.40M derived: sum of 3 quarters · filed 2026-05-14 | $116.73M derived: sum of 4 quarters · filed 2026-05-14 | |||
| 2024-12-31 | $17.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $75.76M derived: sum of 2 quarters · filed 2026-03-05 | $106.09M derived: sum of 3 quarters · filed 2026-03-05 | $137.25M 10-K · filed 2026-03-05 | |||
| 2024-09-30 | $57.85M 10-Q · filed 2025-11-06 | $88.18M derived: sum of 2 quarters · filed 2025-11-06 | $119.34M 10-Q · filed 2025-11-06 | $181.61M derived: sum of 4 quarters · filed 2025-11-06 | |||
| 2024-06-30 | $30.33M 10-Q · filed 2025-08-14 | $61.49M 10-Q · filed 2025-08-14 | $123.76M derived: sum of 3 quarters · filed 2025-08-14 | $149.33M derived: sum of 4 quarters · filed 2025-08-14 | |||
| 2024-03-31 | $31.16M 10-Q · filed 2025-05-15 | $93.42M derived: sum of 2 quarters · filed 2025-05-15 | $119.00M derived: sum of 3 quarters · filed 2025-05-15 | $162.62M derived: sum of 4 quarters · filed 2025-05-15 | |||
| 2023-12-31 | $62.27M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $87.84M derived: sum of 2 quarters · filed 2025-03-20 | $131.46M derived: sum of 3 quarters · filed 2025-03-20 | $158.66M 10-K · filed 2025-03-20 | |||
| 2023-09-30 | $25.57M 10-Q · filed 2024-11-14 | $69.19M derived: sum of 2 quarters · filed 2024-11-14 | $96.39M 10-Q · filed 2024-11-14 | $116.31M derived: sum of 4 quarters · filed 2024-11-14 | |||
| 2023-06-30 | $43.62M 10-Q · filed 2024-08-14 | $70.82M 10-Q · filed 2024-08-14 | $90.74M derived: sum of 3 quarters · filed 2024-08-14 | $120.87M derived: sum of 4 quarters · filed 2024-08-14 | |||
| 2023-03-31 | $27.20M 10-Q · filed 2024-05-09 | $47.12M derived: sum of 2 quarters · filed 2024-05-09 | $77.25M derived: sum of 3 quarters · filed 2024-05-09 | $114.38M derived: sum of 4 quarters · filed 2024-05-09 | |||
| 2022-12-31 | $19.92M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $50.05M derived: sum of 2 quarters · filed 2024-03-28 | $87.18M derived: sum of 3 quarters · filed 2024-03-28 | $179.21M 10-K · filed 2024-03-28 | |||
| 2022-09-30 | $30.13M 10-Q · filed 2023-11-09 | $67.26M derived: sum of 2 quarters · filed 2023-11-09 | $159.29M 10-Q · filed 2023-11-09 | $227.72M derived: sum of 4 quarters · filed 2024-02-09 | |||
| 2022-06-30 | $37.13M 10-Q · filed 2023-08-10 | $129.16M 10-Q · filed 2023-08-10 | $197.59M derived: sum of 3 quarters · filed 2024-02-09 | $242.96M derived: sum of 4 quarters · filed 2024-02-09 | |||
| 2022-03-31 | $92.03M 10-Q · filed 2023-05-11 | $160.46M derived: sum of 2 quarters · filed 2024-02-09 | $205.83M derived: sum of 3 quarters · filed 2024-02-09 | $240.89M derived: sum of 4 quarters · filed 2024-02-09 | |||
| 2021-12-31 | $68.43M derived: 8-K 12 month − 10-Q 9 month · filed 2024-02-09 | $113.79M derived: sum of 2 quarters · filed 2024-02-09 | $148.86M derived: sum of 3 quarters · filed 2024-02-09 | $182.89M 8-K · filed 2024-02-09 | |||
| 2021-09-30 | $45.37M 10-Q · filed 2022-11-10 | $80.43M derived: sum of 2 quarters · filed 2022-11-10 | $114.47M 10-Q · filed 2022-11-10 | ||||
| 2021-06-30 | $35.07M 10-Q · filed 2022-08-15 | $69.20M 10-Q · filed 2022-08-15 | |||||
| 2021-03-31 | $34.03M 10-Q · filed 2022-05-13 | ||||||
| 2020-12-31 | $21.99M 10-K · filed 2022-03-31 | ||||||
| 2020-09-30 | $7.25M 10-Q · filed 2021-11-15 | $7.30M 10-Q · filed 2021-11-15 | |||||
| 2020-06-30 | $48.00K 10-Q · filed 2021-09-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |